Introduction {#s1}
============

Ion channels and transporters are progressively emerging as pivotal modulators of different aspects of cancer cell behavior ([@B1]; [@B37]). Such pleiotropic effects can be traced back to the regulation of either V~m~ (an effect mainly exerted by K^+^ channels; [@B28]), or of the concentration and intracellular distribution of specific ion species, such as Ca^2+^ ([@B7]) and H^+^ ([@B20]), or to the direct modulation of intracellular signaling pathways ([@B1]; [@B5]). However, the molecular interactions between these mechanisms are poorly understood, and a unified picture of the cancer cell pathophysiology is still missing.

One of the K^+^ channels most often dysregulated in cancer is K~V~11.1 (or hERG1), which regulates the resting V~m~ in excitable cells ([@B3]), as well as in cancers arising from excitable (e.g. neuroblastomas, [@B14]) and non-excitable tissues. In particular, K~V~11.1 modulates intracellular signaling pathways triggered by integrin-mediated adhesion, both in leukemias ([@B54]) and solid cancers such as the colorectal ([@B15]), pancreatic ([@B38]), gastric ([@B16]) and mammary ([@B4]). The underlying mechanism involves the formation of a macromolecular complex between K~V~11.1 and β1-integrins, which promotes angiogenesis and triggers metastatic spread ([@B15]; [@B4]). In pancreatic ductal adenocarcinoma cells, this occurs through the regulation of f-actin dynamics in filopodia ([@B41]).

Cancer proliferation and migration are also controlled by intracellular pH, whose regulation is frequently dysregulated in tumors ([@B70]). Hence, targeting the pH regulating transporters has been suggested as a therapeutic strategy ([@B53]). Cancer cells generally display a higher activity of the V-type H^+^-ATPases expressed on the plasmalemma ([@B62]), the Na^+^/H^+^ exchanger NHE1 ([@B65]), the monocarboxylate transporters (MCTs) ([@B56]), the Na^+^/HCO~3~^-^ cotransporters (NBCs) ([@B21]), and the membrane-associated carbonic anhydrases (CAs), such as CA II and CA IX ([@B45]). The concerted activity of these proteins generally leads to an inverted transmembrane pH gradient, characterized by alkalization of intracellular pH (pH~i~) and extracellular acidosis. This is considered a hallmark of cancer metabolism ([@B63]), being associated with increased tumor proliferation, invasion, metastasis, and thus higher aggressiveness and resistance to treatment ([@B46]). Both the pH~i~ alkalinization and the extracellular acidosis sustained by the higher activity of H^+^ transporters in cancer cells promote cell proliferation, escape from apoptosis and metabolic adaptation ([@B70]). In addition, the inverted pH gradient is involved in the control of cell migration ([@B70]). An acid extracellular environment favors the formation of invadopodia and activates proteases that degrade the extracellular matrix, hence favoring cancer cell motility and invasiveness ([@B9]). Conversely, an alkaline pH~i~ stimulates cell motility by promoting cytoskeleton assembly and focal adhesion remodeling ([@B64]; [@B19]), and hence is one of the main hallmarks of metastatic tumors ([@B67]). In this scenario, a pivotal role is exerted by integrin receptors and by the Na^+^/H^+^ antiporter NHE1, whose reciprocal regulatory interaction was discovered in the late eighties ([@B60]; [@B17]). In particular, NHE1 is stimulated by cell adhesion, and in turn regulates cell attachment and spreading onto fibronectin ([@B26]; [@B66]). In migrating cells, the production of a pH~i~ gradient along the axis of movement accompanies the accumulation of NHE1 at the migrating front, which localizes close to integrins ([@B24]; [@B57]; [@B40]). The acidic pericellular environment at the leading edge is thought to increase the pH~e~-dependent avidity of integrins, which facilitates cell-matrix interactions and modulates adhesion strength ([@B39]; [@B18]; [@B68]; [@B69]). The corresponding local pH~i~ increase stimulates the focal adhesion dynamics. First, it supports the F-actin severing activity of cofilin ([@B19]), which produces free-barbed-end actin in the lamellipodium. Second, it reduces the affinity of talin for actin ([@B64]). It is thus clear that the pH regulating mechanisms are essential determinants of the tumor microenvironment and the cancer cell crosstalk.

Based on the above premises, we investigated whether the pH-regulating transporters are functionally linked to K~V~11.1 channels, which are strongly dysregulated in cancer cells, and whose activity is tightly related to integrin receptors in modulating cancer cell proliferation and migration ([@B5]). In particular, we studied if pH regulating mechanisms provide a direct link between integrin-mediated hERG1-dependent cell adhesion and the tumor microenvironment. As a model, we used ColoRectal Cancer (CRC) cells, in which knowledge about K~V~11.1 physiology is particularly extensive.

Materials and Methods {#s2}
=====================

Unless otherwise indicated, chemicals and drugs were purchased from Sigma-Aldrich (St. Louis, USA).

Cell Lines and Cell Culture {#s2_1}
---------------------------

The human colon carcinoma cell lines HCT 116 and HT 29 were cultured at 37°C and 5% CO~2~ in air, in Roswell Park Memorial Institute (RPMI) 1640 Medium, with sodium bicarbonate (2 g/L) and 2mmol/L L-glutamine ("culture medium"), supplemented with 10% fetal bovine serum (FBS) (Euroclone, Italy). In all experiments, cells were starved overnight in culture medium without serum ("no-serum medium") and detached, prior to experiment, with PBS plus 5 mM EDTA.

Coating of Culture Substrates {#s2_2}
-----------------------------

Extracellular Matrix (ECM) proteins at the final amount per cm2 of surface area shown in brackets: Fibronectin (FN, 5 μg), Collagen-1 \[Col-1, 10 μg; produced as reported in [@B25]\], Vitronectin \[VN, 0.5 μg; produced as reported in [@B71]\]. Coating with Polylysine (PL, 0.1 µg) was taken as a control of integrin-independent adhesion, while seeding onto uncoated dishes was our "no-adhesion" control. FN and VN were diluted in PBS, Col-1 in serum-free media, PL in bi-distilled water and plated to cover the entire growth surface, followed by 1 h incubation at either 37°C (for Col-1) or room temperature (for FN, VN and PL). After the coating procedure, incubation with Bovine Serum Albumin (BSA) for 15 min at 37°C was performed to block all the uncovered plastic sites.

Measurement of pH~i~ {#s2_3}
--------------------

To determine pH~i~, we used 2′,7′-Bis (2-carboxyethyl)-5 (6)-carboxyfluorescein acetoxymethyl esther (BCECF-AM). Cells were starved and detached as described above, and seeded (5 x 10^4^ cells/well) in no-serum medium onto uncoated or coated (see above) 96-well plates (clear bottom 96-well plate, polystyrene, TC-treated, clear flat bottom wells, sterile, w/lid, black; Corning, New York, USA). Cells were then incubated at 37°C in 5% CO~2~ for different times, in the absence or presence of different drugs (see below). At selected time points, the medium was removed and BCECF-AM (1μM ﬁnal concentration in loading solution (HBSS 1X plus 0.01% NaHCO~3,~ pH 7)) was added for 30 min at 37°C and 5% CO~2~. After incubation, cells were washed twice with loading solution at room temperature. For measurement of initial (time 0) pH~i~, cells were detached, kept in suspension in a 1.5 ml tube and incubated in BCECF-AM-containing solution for 30 min at 37°C. Next, they were washed twice with loading solution, poured in a 96-well plate at 5x10^4^ cells/well at room temperature, and immediately transferred to the microplate reader. Fluorescence intensity was immediately measured with a microplate reader (Infinite 200 PRO, Tecan, Switzerland) set at the following wavelengths: 440--490nm for excitation and 535 nm for emission. A calibration curve was set up using a high K^+^/Nigericin solution (135 mM KCl, 2 mM K~2~HPO~4~, 20 mM HEPES, 1.2 mM CaCl~2~ and 0.8 mM MgSO~4~), in a range of pH from 5.0 to 8.5. All pH values were calculated using 490/440nm ﬂuorescence ratio and applying standard curve and linear equations, as detailed in [@B23].

Modulators of β1 Integrin-Mediated Adhesion {#s2_4}
-------------------------------------------

The mouse monoclonal anti-β1 integrin antibody BV7 (anti-β1 Ab, kindly gifted by Prof. P. Defilippi, University of Turin, Italy) ([@B42]) was used to block β1-integrins as described in [@B27]. Briefly, cells were seeded onto Col-I in no serum medium, containing anti-β1 Ab (20 μg/ml), for 90 min at 37°C and 5% CO~2.~ Cells (mostly detached) were collected, and pH~i~ mesaurement was performed as above described for time zero condition.

Modulators of pH-Regulating Transporters and K~V~11.1 {#s2_5}
-----------------------------------------------------

We used the following compounds: 100 µM acetazolamide (CA inhibitor; [@B50]), 10 µM amiloride (inhibitor of NHE1 and epithelial Na^+^ channel, ENaC; [@B43]), 5 µM cariporide (specific NHE1 inhibitor; [@B30]), 30 µM S0859 (NBC inhibitor; [@B30]), and 40 µM E4031 (Tocris, Bristol, UK; K~V~11.1 blocker; [@B44]),

Drugs were added to the cells seeded on uncoated or coated surfaces at different time points. Preliminarily, all compounds were tested for their potential cytotoxic effects at all the used concentrations, by measuring cell viability with the trypan blue test ([@B55]), at 30, 90 and 180 min of incubation. None of the modulators had any cytotoxic effect ([**Table 1**](#T1){ref-type="table"}).

###### 

Percentage of alive cells after ICT modulators treatment for 30, 90, and 180 min (± s.e.m).

                      30′              90′             180′                                            
  ------------------- ---------------- --------------- --------------- --------------- --------------- ---------------
  **Acetazolamide**   99.01 ± 0.004    99.02 ± 0.004   98.02 ± 0.003   99.01 ± 0.009   97.02 ± 0.004   96.03 ± 0.004
  **Amiloride**       99.02. ± 0.002   98.01 ± 0.008   99.03 ± 0.002   99.01 ± 0.002   98.02 ± 0.002   98.01 ± 0.004
  **Cariporide**      98.01 ± 0.001    98.02 ± 0.001   99.01 ± 0.001   98.01 ± 0.001   98.03 ± 0.015   98.01 ± 0.001
  **S0859**           99.02 ± 0.004    99.01 ± 0.004   98.01 ± 0.003   99.03 ± 0.009   97.01 ± 0.004   96.02 ± 0.004
  **E4031**           99.01 ± 0.005    99.04 ± 0.003   99.01 ± 0.004   99.02 ± 0.005   99.01 ± 0.005   99.03 ± 0.007

Lateral Motility Assay {#s2_6}
----------------------

Lateral motility was determined using 35 mm dishes and drawing 15 horizontal lines and 3 perpendicular lines on the dish bottom to generate a grid system. Plates were coated with Col-I and 5x10^5^ cells were seeded and allowed to attach for 90 min. Three wounds were drawn following the 3 horizontal lines. Subsequently, the following treatments were performed with drugs diluted in RPMI medium: control, E4031 40 µM, E4031 40 µM + cariporide 5 µM. Then, the distances between cells were measured at each mark point (where the 3 horizontal lines crossed the 15 vertical lines) using a light microscope. The widths measured at time 0 correspond to the W~0~ parameter. These different 45 points were measured again after 90′. Motility Index (MI) was assessed using the following formula: MI = 1 -- W~t~/W~0~, where W~t~ is the width of the wounds after 90′.

Each treatment was performed in triplicate and the experiments were carried out at least 3 times.

Co-Immunoprecipitation Experiments {#s2_7}
----------------------------------

For (co)-immunoprecipitation experiments cells were seeded and incubated on Col-I. Cells were gently collected by mild scraping and resuspended in ice cold PBS. Protein extraction, quantification and total lysate incubation with protein A/G agarose beads (Santa Cruz Biotechnology, Texas, USA) were performed as previously reported ([@B4]). In particular, the composition of the lysis buffer was the following: NP40 (150 mM), NaCl (150 mM), Tris-HCl pH 8 (50 mM), EDTA pH 8 (5 mM), NaF (10 mM), Na~4~P~2~O~7~ ~(~10 mM), Na~3~VO~4~ (0.4 mM), and protease inhibitor cocktail (cOmplete Mini-Roche, Germany).

The following antibodies were used at the concentration of 5µg per mg of extracted proteins: LEAF Purified anti-human, Clone TS2/16 (BioLegend, California, USA) to immunoprecipitate the β1-integrin; mAb K~V~11.1 (MCK Therapeutics, Italy) to immunoprecipitate K~V~11.1. After overnight incubation, the immuno-complex was captured by adding 30 µl of protein A/G agarose beads for 2 h at 4°C (with rolling agitation). The agarose beads were washed 3 times in ice-cold wash buffer and 3 times in ice cold PBS followed by addition of 2X Laemli buffer (10 µl) and boiled for 5 min at 95°C. Afterwards, SDS-PAGE was performed. After electrophoresis, proteins were transferred onto PVDF membrane (previously activated) in blotting buffer under cold condition for 1 h at 100 V. The PVDF membrane was then blocked with 5% BSA in T-PBS (0.1% tween) solution for 3h at room temperature to cover the unspecific antibody binding sites on the membrane. SDS-PAGE and antibody incubation were performed as previously described ([@B4]). The following antibodies were used: anti β1-integrin, RM-12, polyclonal rabbit antibody, dilution 1:1,000 (Immunological Science, Italy); anti-Kv11.1, C54 polyclonal rabbit antibody, dilution 1:1,000 (DI.V.A.L TOSCANA S.R.L., Italy); anti-NHE1 polyclonal rabbit antibody, dilution 1:500 (Novus Biologicals, Colorado, USA) and anti-tubulin, monoclonal mouse, dilution 1:500 (Santa Cruz Biotechnology, Texas, USA). The following day the membrane was washed with T-PBS (0.1% tween) (15 min x 3 times) and appropriate secondary antibody: (i) conjugated with peroxidase enzyme was dissolved in 5% BSA in T-PBS (0.1% tween) (dilution 1:10.000) for at least 45 min and washed (15 min x 3 times), revealing was performed using ECL solution in dark room (anti-C54 primary antibody) and (ii) for all other primary antibodies, IRDYe 800 CW (LI-COR Biosciences, Nebraska, USA) was dissolved in 5% BSA in T-PBS (0.1% tween) (dilution 1:20.000) for at least 45 min and washed (15 min x 3 times) before membrane scanning using LI-COR Odyssey Scanner (Biosciences, Nebraska, USA).

Protein Quantification {#s2_8}
----------------------

Data were analyzed with ImageJ and graphs were plotted with OriginPro8. When quantifying variations in K~V~11.1-β1 integrin interaction, the signal for co-immunoprecipitated protein was first divided by the signal of the protein used for immunoprecipitation and then normalized to the signal of the corresponding protein in the total lysate.

Statistical Analysis {#s2_9}
--------------------

OriginPro8 was used for analysis. Data groups were tested for normality (Shapiro-Wilk test) and variance homogeneity (Welch test). Statistical significance for two sample analysis was carried out with unpaired t-test. Multiple comparisons were carried out by One-way ANOVA, with post-hoc Bonferroni test. A p value ≤ 0.05 was considered statistically significant.

Results {#s3}
=======

Cell Adhesion Mediated by β1 Integrin Produces an Early pH~i~ Alkalinization in HCT 116 and HT 29 CRC Cells {#s3_1}
-----------------------------------------------------------------------------------------------------------

HCT 116 and HT 29 cells were incubated in serum-free medium for different times (0--180 min) onto different ECM substrates: Col-I, FN, and VN. Polylysine or no-coated plastic surfaces were used as integrin-independent or "no-adhesion" controls, respectively. At different time points, pH~i~ was determined by BCECF-AM. Although with slightly different time courses, both cell lines underwent an early pH~i~ increase between 0 and 90 min ([**Figures 1A, B**](#f1){ref-type="fig"}). At 90 min of incubation, pH~i~ was significantly higher in cells seeded onto Col-I and FN, i.e., two substrates recognized by β1 integrins, which are well expressed in both cell lines ([**Table 2**](#T2){ref-type="table"}). Indeed, treatment with a β1 integrin blocking antibody (BV/, [@B42]) (indicated as "anti-β1 Ab" in [**Figure 1**](#f1){ref-type="fig"}) not only blocked cell adhesion (panel A' and B'), but also prevented the pH~i~ increase triggered by cell adhesion onto Col-I. In particular, pH~i~ increased from 6.7 at time 0 (i.e., before seeding) to 7.2 at 90 min in cells seeded either onto Col-I or FN. In contrast, pH~i~ remained close to the time 0 value (6.74±0.006 for HCT 116 and 6.66±0.014 for HT 29) in CRC cells seeded onto Col-I and treated with the anti-β1 Ab (insets to [**Figures 1A, B**](#f1){ref-type="fig"}). The pH~i~ alkalinization was much smaller in cells seeded onto VN (in agreement with the very low expression of β3-integrins in both cell lines, see [**Table 2**](#T2){ref-type="table"}), or polylysine or no-coating conditions. Subsequently (i.e., after 90 min of incubation), the pH~i~ observed in cells seeded on Col-I and FN progressively returned to the control value. At 180 min, cells displayed a pH~i~ around 7.0, irrespective of growing conditions ([**Figures 1A, B**](#f1){ref-type="fig"}). Such values were maintained for at least 24 h (the complete data set is given in [**Table 3**](#T3){ref-type="table"}). We conclude that the β1 integrin-mediated adhesion triggers an early and transient pH~i~ alkalinization from 6.7 to 7.2 in CRC cells.

![Effect of Collagen I, Fibronectin, and Vitronectin on pH~i~ in HCT 116 and HT 29 cells. The time course of pH~i~ is reported in panel **(A)** (HCT 116) and in panel **(B)** (HT 29). Simbol ▪: No coating surface, •: PL coating, ▲: Col-I coating, ▼: FN coating, ♦: VN coating, ○: Col-I anti-β1 Ab. On the right of the panel, 90 min pH~i~ values are reported. Light grey bar: No coating surface, dark grey bar: Col-I, black bar: FN and striped bar: Col-I anti-β1 Ab. Number represent mean ± s.e.m (of three different experiments). \*, *P* \< 0.05; \*\*, *P* \< 0.01 and \*\*\*, *P* \< 0.001. *p value after 30 min of seeding, panel* **(A)**: *\*\*\*P* \< 0.001: Col-I vs Control: 0.0005, FN vs Control: 0.0005; *p value after 90 min of seeding, panel* **(A)**: *\*\*\*P* \< 0.001: Col-I vs Control: 0.0001, FN vs Control: 0.0001; *\*P* \< 0.05: No coat vs Control: 0.01, PL vs Control: 0.01 and VN vs Control: 0.02*. p value after 180 min of seeding, panel* **(A)**: *\*P* \< 0.05: No coat vs Control: 0.01, PL vs Control: 0.01 and VN vs Control: 0.01, Col-I vs Control: 0.01, FN vs Control: 0.01. *p value after 30 min of seeding, panel* **(B)** *\*\*\*P* \< 0.001: Col-I vs Control: 0.0001 and FN vs Control: 0.0001; *p value after 90 min of seeding, panel* **(B)** *\*\*\*P* \< 0.001: Col-I vs Control: 0.0001 and FN vs Control: 0.0001; *\*P* \< 0.05: No coat vs Control: 0.01, PL vs Control: 0.01 and VN vs Control: 0.01*. p value after 180 min of seeding, panel* **(B)** *\*P* \< 0.05: No coat vs Control: 0.01, PL vs Control: 0.01, VN vs Control: 0.01, Col-I vs Control: 0.01 and FN vs Control: 0.01. *p value after 30 min of seeding, panel* **(A)**: *\*\*\*P* \< 0.001: Col-I vs No coat: 0.001 and FN vs No coat: 0.001*. p value after 90 min of seeding, panel* **(A)**: Col-I vs No coat: 0.0001, FN vs No coat: 0.0001; Col-I anti-β1 Ab vs Col-I: 0.0007; Col-I anti-β1 Ab vs FN: 0.0006. *p value after 30 min of seeding, panel* **(B)** *\*\*\*P* \< 0.001: Col-I vs No coat: 0.001 and FN vs No coat: 0.001*. p value after 90 min of seeding, panel* **(B)** Col-I vs No coat: 0.001 and FN vs No coat: 0.001. Col-I anti-β1 Ab vs Col-I: 0.0006; Col-I anti-β1 Ab vs FN: 0.0005. Representative images of cells seeded for 90 min on Col-I, no treated and treated with anti-β1 Ab are reported in panels A^I^ (HCT 116) and B^I^ (HT 29), 100 µm scale bar. The conditions are shown on the top of each picture. Cells seeded on Col-I are elongated and attached, cells seeded on Col-I and treated with anti-β1 Ab are round and detached.](fphar-11-00848-g001){#f1}

###### 

Integrin profile and ICT expression of HCT 116 and HT 29 cell lines.

                                         HCT 116                   HT 29
  -------------------------------------- ------------------------- -------------------------
  **α~1~β~1(Col-I)~, α~2~β~1(Col-I)~**   \+ ^([@B8];^ ^[@B22])^    \+ ^([@B8];^ ^[@B52])^
  **α~3~β~1(FN),~ α~4~β~1(FN)~**         \+ ^([@B52];^ ^[@B32])^   \+ ^([@B22];^ ^[@B32])^
  **α~5~β~1(FN)~**                       \+ ^([@B52])^             \- ^([@B59])^
  **α~8~β~1(FN)~**                       \- ^([@B6])^              \- ^([@B6])^
  **α~V~β~3(FN),~ α~V~β~3(VN)~**         \- ^([@B52])^             \- ^([@B12])^
  **α~V~β~6(FN)~**                       \+ ^([@B34])^             \+ ^([@B34])^
  **Kv 11.1**                            \+ ^([@B55])^             \+ ^([@B55])^
  **CA IX**                              \- ^([@B47])^             \+ ^([@B47])^
  **NHE1**                               \+ ^([@B29])^             \+ ^([@B29])^
  **NBCe1**                              \+ ^([@B29])^             \+ ^([@B29])^
  **MCT1**                               \+ ^([@B33])^             \+ ^([@B33])^
  **MCT4**                               \+ ^([@B11])^             \+ ^([@B11])^

###### 

Complete set of raw pH~i~ values.

  HCT 116           0'             30'            90'            180'           360'           1440
  ----------------- -------------- -------------- -------------- -------------- -------------- --------------
  **No Coating**    6.70 ± 0.008   6.82 ± 0.005   6.96 ± 0.045   7.00 ± 0.003   7.10 ± 0.004   7.12 ± 0.013
  **Polylysine**    6.70 ± 0.008   6.75 ± 0.036   7.03 ± 0.011   7.02 ± 0.012   7.12 ± 0.013   7.12 ± 0.012
  **Collagen I**    6.70 ± 0.008   7.15 ± 0.009   7.26 ± 0.007   7.01 ± 0.005   7.11 ± 0.008   7.01 ± 0.015
  **Fibronectin**   6.70 ± 0.008   7.16 ± 0.023   7.29 ± 0.026   7.08 ± 0.004   7.05 ± 0.014   7.18 ± 0.04
  **Vitronectin**   6.70 ± 0.008   6.77 ± 0.011   6.98 ± 0.016   6.99 ± 0.045   7.00 ± 0.025   7.10 ± 0.015
  **HT 29**         **0'**         **30'**        **90'**        **180'**       **360'**       **1440**
  **No Coating**    6.65 ± 0.014   6.81±0.035     7.00 ± 0.021   6.99 ± 0.01    7.09 ± 0.01    7.09 ± 0.01
  **Polylysine**    6.65 ± 0.014   6.84 ± 0.096   6.99 ± 0.006   7.12 ± 0.02    7.16 ± 0.001   7.16 ± 0.001
  **Collagen I**    6.65 ± 0.014   7.22 ± 0.037   7.21 ± 0.005   7.03 ± 0.027   7.11 ± 0.023   7.11 ± 0.023
  **Fibronectin**   6.65 ± 0.014   7.21 ± 0.042   7.26 ± 0.024   6.98 ± 0.006   7.03 ± 0.028   7.03 ± 0.028
  **Vitronectin**   6.65 ± 0.014   6.84 ± 0.037   6.98 ± 0.027   6.99 ± 0.011   7.01 ± 0.017   7.01 ± 0.017

The pH~i~ Variations Triggered by β1 Integrin-Dependent Adhesion in CRC Cells Depend on NHE1 Activation and Are Modulated by K~V~11.1 Activity {#s3_2}
----------------------------------------------------------------------------------------------------------------------------------------------

To better determine the mechanism of integrin-dependent pH~i~ increase, we applied blockers of the different pH-regulating transporters expressed in CRC cells ([**Table 2**](#T2){ref-type="table"}). In particular, we tested acetazolamide (a wide CA inhibitor), amiloride (an NHE blocker, in particular of NHE1, as well as of ENaC), cariporide (a specific NHE1 inhibitor), and S0859 (an inhibitor of all NBCs). Drugs were used at the concentrations indicated in Materials and Methods, on cells seeded onto Col-I for 90 min, since the beginning of the experiment. Acetazolamide had no effect on pH~i~ of either cell line, whereas both amiloride and cariporide produced a statistically significant decrease of pH~i~ which reached values comparable to those detected in cells before seeding (dotted line in [**Figure 2**](#f2){ref-type="fig"}). The same effect was produced by cariporide. The treatment with S0859 produced a reduction of pH~i~, although much lower compared to that obtained with amiloride ([**Figures 2A, B**](#f2){ref-type="fig"}).

![Effect of Acetazolamide, Amiloride, S0859, Cariporide, E4031, and E4031 plus Cariporide on pH~i~ in cells seeded on collagen I, 90 min treatment, in HCT 116 and HT 29 cells. pH~i~ values of HCT 116 are reported in panel **(A)** and for HT 29 in panel **(B)**. Red line: pH~i~ value at time zero. Number represent mean ± s.e.m (of three different experiments). \*, *P* \< 0.05 and \*\*\*, *P* \< 0.001. *p value panel* **(A)**: \*\*\*P \< 0.001: Control vs Amil: 1.9e^\^-05^, Control vs Carip: 1.9e^\^-05^, Control vs E4031: 0.0001, Control vs E4031+Carip: 1.8e\^^-05^Acet vs Carip: 1.7e^\^-05^; \*P \< 0.05: Control vs S0859: 0.03, Acet vs S0859: 0.03, Amil vs S0859: 0.02; Carip vs S0859: 0.02; S0859 vs E4031+ Carip: 0.02. *p value panel* **(B)**: \*\*\*P \< 0.001: Control vs Amil: 1.5e^\^-05^, Control vs Carip: 1.4e^\^-05^, Acet vs Carip: 1.3e^\^-05^; Control vs E4031: 0.0001 and Control vs E4031+Carip: 1.9e\^^-05^; \*P \< 0.05: Control vs S0859: 0.04, Acet vs S0859: 0.03; S0859 vs E4031+ Carip: 0.02.](fphar-11-00848-g002){#f2}

These results suggest that the early alkalinization triggered by β1 integrin-mediated adhesion is mostly sustained by the activity of the Na^+^/H^+^ antiporter NHE1, with a lesser contribution of NBC, and scarse involvement of carbonic anhydrases.

We then tested whether K~V~11.1 was involved in the integrin-dependent pH~i~ alkalinization. To this purpose, cells were treated with the K~V~11.1 blocker E4031, at 40 µM ([@B44]). After 90 min of cell adhesion on Col-I, both HCT 116 and HT 29 cells treated with E4031 showed pH~i~ values significantly more acidic compared to the untreated controls ([**Figures 2A, B**](#f2){ref-type="fig"}). Hence, the activity of K~V~11.1 appears to control NHE1 activation, after β1 integrin-mediated adhesion. This interpretation was supported by the observation that the combined treatment with E4031 and cariporide had no further effect on the pH~i~ value obtained after NHE1 inhibition by cariporide ([**Figures 2A, B**](#f2){ref-type="fig"}).

Blockade of Either NHE1 or K~V~11.1 Inhibits Lateral Motility of CRC Cells {#s3_3}
--------------------------------------------------------------------------

Next, based on the known correlation between pH~i~ and cell motility, we performed experiments of lateral motility on our CRC cell lines, which were seeded onto Col-I for 90 min, and treated with either E4031, or cariporide, or a combination of both. Both cariporide and E4031 produced a statistically significant reduction of the motility index compared to untreated cells ([**Figures 3A, B**](#f3){ref-type="fig"}). The combined treatment with E4031 and cariporide only slightly increased the inhibitory effects of the single treatments on the motility index of either cell line. We conclude that both K~V~11.1 and NHE1 are involved in controlling the β1 integrin-dependent cell motility in CRC cells.

![Effect of E4031 and E4031 plus Cariporide on motility index in cells seeded on col-I, 90 min treatment. Motility index values are reported for HCT 116 in panel **(A)** and for HT 29 in panel C. Number represent mean ± s.e.m (of three different experiments). Representative images are reported in panel **(B)** for HCT 116 and in panel **(D)** for HT 29, 200 µm scale bar. In figure the statistically significant differences between control and treatments are reported. \*\*, *P* \< 0.01. *p value panel* **(A)**: \*\*, *P* \< 0.01: Control vs E4031: 0.002 and Control vs E4031+Carip: 0.001. *p value panel* **(C)**: \*\*, *P* \< 0.01: Control vs E4031: 0.003 and Control vs E4031+Carip: 0.001.](fphar-11-00848-g003){#f3}

β1-Integrin, K~V~11.1, and NHE1 Form a Macromolecular Complex {#s3_4}
-------------------------------------------------------------

We previously showed that cell adhesion onto β1 integrin-dependent substrates (e.g., FN or Col-I), induces K~V~11.1 activation, as well as the formation of a macromolecular signaling complex between the channel and β1 integrin on the plasma membrane of HCT 116 cells ([@B15]). We thus hypothesized that NHE1 could be also recruited in such complex, which could account for the functional cross-talk between integrin receptors, K~V~11.1, and NHE1 in CRC cells. Hence, we seeded HCT116 cells on either uncoated or Col-I-coated surfaces for 90 min, and immunoprecipitated the extracted proteins with anti-β1 integrin or anti-K~V~11.1 antibodies. Blots were then revealed, respectively, with anti-K~V~11.1 or anti-β1 integrin antibodies, as well as with anti-NHE1 antibodies. We observed that β1-integrin co-immunoprecipitated with both K~V~11.1 and NHE1 in CRC cells before cell seeding ("pre seeding" in [**Figure 4**](#f4){ref-type="fig"}), indicating the formation of a β1/Kv11.1/NHE1 complex, whose assembly was further promoted by cell adhesion onto Col-I for 90 min (lanes 3 and 4 in [**Figure 4**](#f4){ref-type="fig"}). On the contrary, in cells seeded onto uncoated surfaces, only a weak co-immunoprecipitation was observed between β1-integrin and K~V~11.1, and no association was observed with NHE1. We conclude that cell adhesion onto Col-I stimulates the formation of a macromolecular complex between β1-integrin, K~V~11.1, and NHE1.

![β1-integrin, K~V~11.1, and NHE1 protein complex. **(A)** Co-immunoprecipitation of β1 Integrin, Kv 11.1 and NHE1 in HCT 116 cells, seeded on no coating surface and Col-I for 90 min. Densitometric analysis is reported in panel **(A)**. In panel A with "WB" is indicated the protein signal in the co-ip and with "INPUT" the protein signal in the total lysate. Pre-seeding condition is reported as pre, No coating as No coat and Collagen I as Col-I; The immunoprecipitation with anti β1 integrin antibody is indicated as IP β1 and with anti K~V~11.1 antibody is reported as IP K~V~11.1. Complex quantification is reported in panel B, black bar: β1-integrin, K~V~11.1 and NHE1 protein complex and white bar: β1-integrin and K~V~11.1 protein complex. Number represent mean ± s.e.m (of three different experiments). \*\*, *P* \< 0.01 and \*\*\*, *P* \< 0.001. *p value panel* **(B)**, \*\*\*, *P* \< 0.001: β1-integrin/K~V~11.1/NHE1 complex, Pre vs Col-I IP β1, p: 0.0008; β1-integrin/K~V~11.1 complex, Pre vs Col-I IP β1, p: 0.00075; β1-integrin/K~V~11.1/NHE1 complex, Pre vs Col-I IP K~V~11.1, p: 0.00076; β1-integrin/K~V~11.1 complex, Pre vs Col-I IP K~V~11.1 p: 0.00074. β1-integrin/K~V~11.1/NHE1 complex, No coat vs Col-I IP β1, p: 1.7e^\^-05^; β1-integrin/K~V~11.1 complex No coat vs Col-I IP β1, p: 0.00072; β1-integrin/K~V~11.1/NHE1 complex, No coat vs Col-I IP K~V~11.1, p: 1.9e^\^-05^; β1-integrin/K~V~11.1 complex, No coat vs Col-I IP K~V~11.1, p: 0.00073. \*\*, *P* \< 0.01: β1-integrin/K~V~11.1/NHE1 complex, Pre vs No coat: 0.002; β1-integrin/K~V~11.1/NHE1 complex vs β1-integrin/K~V~11.1 complex, No coat IP β1: 0.002. Cropped images of blots are reported.](fphar-11-00848-g004){#f4}

Discussion {#s4}
==========

In the present paper, we provide evidence that, in CRC cells, the β1 integrin-mediated adhesion onto ECM proteins such as Col-I and FN triggers an early and transient pH~i~ alkalinization, from 6.7 to 7.2. The effect is caused by NHE1 activation and is modulated by the activity of the voltage-dependent K^+^ channel K~V~11.1. The transporter and the channel appear to cooperate in sustaining the ECM-induced CRC cell motility. Their action is accompanied by the formation of a macromolecular complex between the β1 integrin, K~V~11.1 and NHE1.

The rapid β1 integrin-dependent pH~i~ alkalinization in CRC cells is similar to the one initially reported in bovine capillary endothelial cells ([@B61]), which is also induced by integrin engagement (mainly β1), and sustained by activation of the Na^+^/H^+^ exchanger. In our model, we confirmed the NHE1 involvement by showing that ECM-dependent alkalinization was blocked by cariporide.

Following Schwartz's seminal observation, the pH regulatory role of NHE1 in normal and cancer cells has been receiving increasing attention ([@B65]). In particular, in CRC cells, both H^+^ extrusion through NHE1 and HCO~3~^-^ influx through NBCe1 give a significant contribution to pH~i~ regulation. However, while HCO~3~^-^ influx appears to represent a constitutive element of pH~i~ regulation, the NHE1-mediated H^+^ efflux may vary, depending on culture conditions, e.g. 2D vs 3D cultures ([@B29]). In CRC cells, we found that the Na^+^/HCO~3~^-^ cotransporter, although present, provides only a weak contribution to the integrin-dependent alkalinization in CRC cells. In fact, NHE1 appears to constitute the main molecular device linking the ECM microenvironment to pH~i~ regulation.

Numerous mechanisms leading to NHE1 activation have been described in the various cell types in which the transporter is expressed ([@B48]). Stimuli such as growth factors, peptide hormones etc., which activate receptor tyrosine kinases and G protein-coupled receptors, enhance NHE1 activity, through the involvement of the mitogen-activated, extracellular signal-related kinase (MEK-ERK)-p90rsk. The latter phosphorylates NHE1, and enables its binding to the multifunctional scaffolding protein 14-3-3, which in turn serves as a hub for the assembly of other signaling molecules which eventually enhance cation exchange ([@B48]). In this scenario, it is not surprising that integrins exert a stimulatory role on NHE1, as they are known to trigger intracellular signaling pathways that can lead to NHE1 activation ([@B58]). Integrins, and the tumor microenviroment as a whole, can contribute to trigger a complex signaling pathway which in turn regulates NHE1-dependent motility and invasion in different cancer cells ([@B10]). In particular, NHE1 is linked to the actin cytoskeleton and integrates phosphorylation signals arising from kinases which are involved in cytoskeletal reorganization and cell motility. In addition, NHE1 is preferentially localized in pseudopodia, focal adhesion plates, and invadopodia in migrating cells ([@B49]; [@B51]; [@B13]). In this context, a slight alkalinization mediated by NHE1 was found to regulate the cofilin-mediated actin assembly ([@B19]), a central mechanism in cell protrusion. Hence, NHE1 and cofilin respectively act as a pH regulator and a pH sensor, to mediate actin filament assembly.

The most novel result emerging from our data is that the K~V~11.1 channel is implicated in the pH~i~ alkalinization triggered by integrin-mediated cell adhesion to ECM proteins, and sustained by NHE1 activity. K~V~11.1 is over-expressed in many cancer types, including CRC ([@B35]; [@B36]; [@B15]; [@B31]). In cancers, β1 integrin-mediated adhesion to FN or Col-I activates K~V~11.1, and induces the formation of a macromolecular functional complex on the plasma membrane which comprises the channel and the integrin itself. This occurs preferentially when the channel is in the closed conformation, and leads to the activation of signaling pathways, which also involve the scaffold protein 14-3-3, and in turn control different aspects of cancer cell behavior ([@B4]; [@B5]). The recruitment of NHE1 in the K~V~11.1/β1 integrin complex could give rise to the formation of a signaling hub, facilitating NHE1 activation and hence a localized pH~i~ alkalinization, which in turn could affect the reorganization of actin filaments, presumably regulated by cofilin activation. This agrees with our recent observations in pancreatic ductal adenocarcinoma cells, where K~V~11.1 regulates cell migration through a reorganization of f-actin in stress fibers and a modulation of filopodia formation and dynamics ([@B41]).

The identification of the signaling mechanisms underlying K~V~11.1 and NHE1 interaction triggered by β1 integrin--mediated adhesion needs further experiments. Nevertheless, the interplay between a K+ channel and the pH regulating transporter NHE1 that we describe in the present paper can be considered of relevance in the context of CRC invasiveness/motility. This aspect is often dependent on a complex interaction between cancer cells and the tumor microenvironment, and in particular with ECM proteins like collagens and fibronectin ([@B2]). Finally, targeting the integrin/ion channel/NHE1 molecular hub might represent a therapeutic option to fight cancer invasiveness.
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